Boris Medarov, MD
Pulmonary Disease · Albany, NYNPI 1720055098
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $135,756 of the $160,634 with a category attached, or 84.5%. 17 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 59.0% of the total. 2025 is the largest year on record at $71,874, 5.5 times the $13,062 reported in 2019. Among pulmonary disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 298 payments — averaging $539.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$95K
- Merck$54K
- Bayer$5K
- United Therapeutics Corporation$2K
- GSK$1K
- Jazz Pharmaceuticals Inc.$1K
- plus $3K from 11 others
Across 52 payments — averaging $1313.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$55K
- Actelion Pharmaceuticals, Ltd$9K
- Janssen Research & Development, LLC$3K
- Actelion Pharmaceuticals US, Inc.$1K
What the payments were for
- Consulting fees$5,6003%
- Speaking & faculty fees$135,75685%
- Travel & lodging$8,4625%
- Food & beverage$10,2496%
- Education$5680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 107 | $94,788 |
| Merck | 39 | $53,729 |
| Bayer | 8 | $4,740 |
| United Therapeutics Corporation | 27 | $2,132 |
| GSK | 24 | $1,407 |
| Jazz Pharmaceuticals Inc. | 37 | $1,151 |
| Harmony Biosciences LLC | 31 | $787 |
| AstraZeneca | 7 | $578 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $279 |
| Sanofi | 2 | $250 |
| Astellas Pharma US Inc | 2 | $176 |
| Lilly USA, LLC | 2 | $137 |
| Inspire Medical Systems, Inc. | 2 | $135 |
| CSL Behring | 1 | $123 |
| Boehringer Ingelheim | 1 | $117 |
| Axsome Therapeutics, Inc. | 5 | $88 |
| Apria Healthcare LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$160,634 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 96 | $1,193,164 |
| UptraviSelexipag | 48 | $1,016,052 |
| OpsumitMacitentan | 58 | $700,540 |
| Tyvaso DpiTreprostinil | 21 | $487,012 |
| Ambrisentan | 31 | $186,459 |
| Tadalafil | 54 | $89,896 |
| Orenitram ErTreprostinil Diolamine | 11 | $85,224 |
| Breo ElliptaFluticasone/Vilanterol | 168 | $82,117 |
| NucalaMepolizumab | 22 | $74,940 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 91 | $71,958 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $13,668 |
| Sildenafil Citrate | 23 | $10,315 |
| EliquisApixaban | 14 | $7,764 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,197 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $2,593 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $94,788 | $1,716,592106 claims |
| BayerAdempas | $4,740 | $1,193,16496 claims |
| GSKBreo Ellipta, Nucala, Trelegy Ellipta, Incruse Ellipta | $1,407 | $233,212293 claims |
| AstraZenecaBreztri Aerosphere | $578 | $13,66817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Albany
- Jeffrey WolfGreat Neck$892K
- Keith HarrisPort Jefferson Station$832K
- Jack MannBayside$736K
- Raji AyinlaBronx$673K
- Charles PowellNew York$654K
- Nashat RabadiBuffalo$613K
- Craig ThurmJamaica$604K
- Michael MandelLarchmont$589K
- Sherif El BayadiSyracuse$571K
- Ali El AtatBrooklyn$482K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.